Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 15/20 | 0.73 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536545 | 0.97 | SLC6A9 (0.69) | SLC6A9CTSSCTSK | |
| SCHEMBL4777838 | 0.92 | SLC6A9 (0.61) | SLC6A9CTSSCTSK | |
| SCHEMBL4777842 | 0.92 | SLC6A9 (0.61) | SLC6A9CTSSCTSK | |
| SCHEMBL4726030 | 0.91 | SLC6A9 (0.61) | SLC6A9CTSSCTSK | |
| SCHEMBL4726026 | 0.91 | SLC6A9 (0.61) | SLC6A9CTSSCTSK | |
| SCHEMBL4589972 | 0.89 | SLC6A9 (0.81) | SLC6A9CTSSCTSK | |
| SCHEMBL4780764 | 0.89 | SLC6A9 (0.62) | SLC6A9CTSSCTSK | |
| SCHEMBL4780766 | 0.89 | SLC6A9 (0.62) | SLC6A9CTSSCTSK | |
| Hydrochloric Acid SCHEMBL4588559 | 0.89 | SLC6A9 (0.80) | SLC6A9CTSSCTSK | |
| SCHEMBL8212381 | 0.89 | SLC6A9 (0.60) | SLC6A9CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326722-B2 | N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy | SANOFI-AVENTIS (FR) | 2008-02-05 | — | — | US | disclosed |
| US-20070197601-A1 | Use of N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy | SANOFI-AVENTIS (FR) | 2007-08-23 | — | — | US | disclosed |
| US-20050159450-A1 | Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197601-A1 | Use of N-[Phenyl(piperidin-2-yl)methyl]benzamide derivatives in therapy | SLC1A2, SLC1A1, SLC1A5 | SLC6A9 53/4885CTSS 3102/4885CTSK 3396/4885 |
| US-20050159450-A1 | Derivative of n-[phenyl(piperidin-2-yl)methyl]benzamide, the preparation method thereof and application of same in therapeutics | NPR3, NR4A3, PRMT3 | SLC6A9 4691/4885CTSS 3277/4885CTSK 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.